Evoke Wealth’s Myriad Genetics MYGN Stock Holding History

Evoke Wealth’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,626	Closed	-$44.3K	–	1277
2019 Q4	$44.3K	Buy	1,626 +78	+5%	+$2.15K	0.01%	441
2019 Q3	$44.3K	Buy	+1,548	New	+$45.1K	0.01%	494

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Evoke Wealth's MYGN Position: Q1 2020 in Review

Evoke Wealth sold out of Myriad Genetics (MYGN) in Q1 2020, closing a stake of 1,626 shares — an estimated $44.3K sold.

Evoke Wealth first reported a position in MYGN in Q3 2019 and held it in 2 quarters. The position peaked at $44.3K in Q3 2019. 190 funds tracked by Wall St. Rank hold MYGN as of Q1 2020.

Evoke Wealth reported no remaining Myriad Genetics position as of Q1 2020 after selling out during the quarter.
Evoke Wealth sold 1,626 Myriad Genetics shares in Q1 2020, an estimated $44.3K.
Evoke Wealth first reported a position in Myriad Genetics in Q3 2019 and held it in 2 quarters.
Evoke Wealth's Myriad Genetics position peaked at $44.3K in Q3 2019.
190 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2020.

Based on Evoke Wealth's 13F filing for Q1 2020, filed 7 May 2020.